Pharma’s ‘No-Show’ At Regulatory Meetings In India: Who Loses?

 
• By Anju Ghangurde
  
Chairs
DRUG FIRMS FAIL TO SHOW UP AT REGULATORY MEETINGS IN INDIA

More from Review Pathways

More from Pathways & Standards